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We investigated the current perception threshold (CPT) of epileptic patients treated with valproate. The CPTs at frequencies
of 5 Hz, 250 Hz and 2000 Hz in the control group of patients were 198.9 ± 15.8, 62.0 ± 18.9 and 35.3 ± 15.8, respectively.
The CPTs at 5 Hz, 250 Hz and 2000 Hz in the epileptic group of patients were 350.6 ± 61.3, 338.6 ± 64.3 and 193.2 ± 21.1,
respectively. The CPTs at 5 Hz, 250 Hz and 2000 Hz in the epileptic group were significantly higher than those of the control
group. We measured the CPTs for 6 months after the administration of valproate in three patients with traumatic epilepsy. Their
CPTs were higher than that of the epileptic group. The CPTs at 5 Hz, 250 Hz and 2000 Hz reached a maximum 4 weeks after the
administration of valproate for two of these patients and in 6 weeks for the other patient. When the administration of valproate
to a patient was stopped, CPTs decreased.
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INTRODUCTION
Pain perception thresholds of patients with epilepsy
are suggested to be higher than those of healthy sub-
jects1. These patients do not complain of pain, in
spite of having severe traumatic lesions1. The lack
of pain in patients with epilepsy is considered to re-
sult from either the epileptic condition or its treat-
ment. Antiepileptic drugs are known to have strong
analgesic effects2 and are used for the therapy of neu-
ropathic pain and migraine3. Valproate is often pre-
ferred to carbamazepine, phenytoin, benzodiazepines
and phenobarbitones because valproate may be better
tolerated4, 5. Valproate easily crosses the blood–brain
barrier and increases γ -aminobutyric acid (GABA)
concentration in various areas of the CNS6. GABA is
the most important inhibitory neurotransmitter in the
brain and plays a role in analgesia7 as well as epilepsy.
On the other hand, an increase in β-endorphin lev-
els has been reported to occur in the CSF of patients
with epilepsy8. However, their β-endorphin levels are
normal during seizure-free periods9. Thus, it is possi-
ble that the lack of pain during seizure-free periods is
caused by anticonvulsants.
Pain has been subjectively assessed by means of ver-
bal or visual intensity scales. However, it has recently
become possible to objectively evaluate human pain
threshold levels using the neurometer. The neurometer
is a non-invasive device and can measure the sensi-
tivity to electric current or current perception thresh-
old (CPT)10. It can test different types of nerve fibres
by using different frequencies of electric stimulation;
2000 Hz for Aβ, 250 Hz for Aσ and 5 Hz for C fi-
bres11. There is no previous data on CPT testing in
epileptic patients treated with valproate. Therefore, in
the present study, we set out to assess peripheral sen-
sory nerve function in epileptic patients treated with
valproate.
PATIENTS AND METHODS
The study was approved by our institutional medi-
cal ethics committee. Informed consent was obtained
from each patient. We studied 14 epileptic patients,
ranging in age from 22 to 40 years and 25 patients
as the control, ranging in age from 16 to 45 years.
The 25 control patients were randomly selected out of
healthy patients and were not treated with any medi-
cation. The diagnosis of epilepsy was made by neurol-
ogists. The epileptic patients had been given a daily
dose of 300–900 mg of valproate in three divided
1059–1311/00/070498 + 04 $35.00/0 c© 2000 BEA Trading Ltd
Current perception thresholds of epileptic patients treated with valproate 499
doses. The dose of medication had been stable for at
least a year before the study. These epileptic patients
were treated with valproate for at least 3 years be-
fore the study and were not treated with any other
antiepileptic drugs. All patients had been seizure-free
for more than 120 hours when undergoing these tests.
None of these patients were suffering from peripheral
neuropathic disorder or central pain.
Assessment for peripheral sensory nerve function
was performed in a quiet room by Neurometer CPT
(Toyomedic, Tokyo, Japan) the day before the op-
eration. The test was performed by physiotherapists
who did not have any knowledge or information about
the study. The equipment is a neuroselective transcu-
taneous electric stimulator which generates a sinu-
soidal waveform from a constant current stimulator,
adjustable from 0 to 10 milliamperes (mA). The low-
est level of painless electric stimulus required to evoke
a sensation was determined for 2000 Hz, 250 Hz and
5 Hz frequencies on the right index finger. The 5 Hz
frequency has been shown to correlate with C fibre
function as measured with quantitative thermal and
pain sensation. The 250 Hz and 2000 Hz frequen-
cies have been shown to correlate with Aσ and Aβ
fibre function as measured with sensory nerve con-
duction and quantitative vibratory evaluations. Two
small gold-plated surface electrodes were applied: one
on the lateral and the other on the medical aspect of
the index finger. The current was slowly increased un-
til the patient reported sensation. The stimulation was
turned off, then the intensity was lowered 100 µA and
the stimulation was turned back on. This procedure
was repeated until a range of 100 µA was established,
at which level the patient reported feeling the high
intensity and could not perceive the lower intensity.
Using a standardized double-blind methodology, the
patient was then presented with a minimum of six cy-
cles of randomly selected real and false stimulations,
above and below their perception threshold level, until
the exact CPT value was determined within a±20 µA
range. CPT scores define 0.01 mA as ‘1’ and 10 mA
as ‘1000’.
Plasma valproate levels were measured using a
fluorescence polarization immunoassay method. The
plasma levels of valproate were expressed as the aver-
age of three measurements.
The Wilcoxon and Mann–Whitney U -tests were
used for data analysis and a P < 0.05 was considered
significant. All data were presented as mean ± SEM.
RESULTS
There were no significant differences in age, weight
or height between the control group and the epilep-
tic group. The CPTs at 5 Hz, 250 Hz and 2000 Hz in
the control group were 198.9± 15.8, 62.0± 18.9 and
35.3 ± 15.8, respectively. The CPTs at 5 Hz, 250 Hz
and 2000 Hz in the epileptic group were 350.6± 61.3,
338.6±64.3 and 193.2±21.1, respectively. The CPTs
at 5 Hz, 250 Hz and 2000 Hz in the epileptic group
were significantly higher than those of the control
group.
Mean plasma concentration of valproate was
36.2 µg ml−1. We could not find a correlation be-
tween CPTs and plasma valproate levels (CPT at 5 Hz
vs. plasma valproate levels, r = 0.51, P = 0.06;
CPT at 250 Hz vs. plasma valproate levels, r = 0.43,
P = 0.12; CPT at 2000 Hz vs. plasma valproate lev-
els, r = 0.44, P = 0.11) or between CPTs and du-
ration of its administration (CPT at 5 Hz vs. duration,
r = 0.34, P = 0.24; CPT at 250 Hz vs. duration,
r = 0.17, P = 0.56; CPT at 2000 Hz vs. duration,
r = 0.01, P = 0.98).
We measured CPT prior to and for 6 months after
the administration of valproate in three patients with
traumatic epilepsy. Their CPTs were higher than that
of the epileptic group. The CPTs at 5 Hz, 250 Hz and
2000 Hz reached a maximum 4 weeks after the admin-
istration of valproate for two of these patients and in
6 weeks for the other patient.
DISCUSSION
The present study demonstrated that epileptic patients
treated with valproate had increased CPTs at frequen-
cies of 5 Hz, 250 Hz and 2000 Hz. Valproate is
one of the major antiepileptic drugs and is also used
for the therapy of neuropathic pain3. Valproate in-
creases GABA synthesis, reduces neuronal excitation
induced by NMDA-type glutamate receptors and al-
ters serotonergic function12. Inhibition of GABA and
NMDA receptors attenuates or inhibits nociceptive re-
sponse13, 14. Thus, the actions of valproate on GABA
receptors, NMDA receptors and serotonin appear to
contribute to increased CPTs. In this study, an in-
crease in CPTs at 5 Hz and 250 Hz was more re-
markable than that of CPTs at 2000 Hz. Stimulation
of C fibres induced by pinch and heat is inhibited by
GABA agonists15, but the relationship between Aβ,
Aσ and GABA receptors is unknown. Local anaes-
thetic blockade of peripheral nerves also selectively
elevates the 5 Hz and 250 Hz thresholds without af-
fecting the 2000 Hz threshold and the same finding is
found by intravenous lidocaine administration16. The
mechanism by which valproate and lidocaine do not
affect the 2000 Hz threshold remains unclarified, but
it is interesting that both drugs show the same phe-
nomenon. Probably, valproate and lidocaine can pro-
duce a selective block of Aσ and C fibres in spinal
cord or supraspinal lesions. Thus, valproate may have
more influence on small nerve fibres.
500 A. Kudoh & A. Matsuki
Table 1: Profile of epileptic patients (12 tonic–clonic generalized seizure (TCGS) and 2 temporal lobe seizure (TLS)).
Age/Sex Begining of the disease Type of seizure Plasma valproate CPT
(years) concentration (µg ml−1) 5 Hz 250 Hz 2000 Hz
38/F 8 TCGS 36.7 242 359 413
32/F 4 TCGS 46.6 251 340 337
36/F 10 TCGS 15.8 360 240 223
40/M 18 TCGS 56.3 662 245 217
38/M 4 TCGS 45.6 263 263 204
22/F 3 TCGS 26.8 168 65 169
31/M 6 TCGS 40.8 132 78 311
30/M 6 TCGS 57.5 850 938 980
28/F 7 TCGS 29.5 62 347 372
29/F 11 TLS 63.7 71 335 342
30/F 9 TLS 33.8 37 469 280
28/M 10 TCGS 14.1 74 384 359
35/F 3 TCGS 28.2 45 31 192
33/M 5 TCGS 11.5 28 67 126
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Fig. 1: Current perception threshold test prior to and for 6 months after the administration of valproate in three patients with trau-
matic epilepsy. Valproate administered to the patient represented by N was stopped 6 weeks after the start of its administration.
Table 2: Current perception threshold test in epileptic pa-
tients treated with valproate and control patients. Data are
expressed as mean ± SEM. ∗P < 0.05, ∗∗∗P < 0.001, vs.
control group.
Ranges Control group Epilepsy group
2000 Hz 176.9± 20.5 323.2± 55.5∗ß
250 Hz 61.7± 6.9 297.2± 61.6∗∗∗
5 Hz 37.0± 4.3 231.8± 66.0∗∗∗
An increase in β-endorphin levels has been re-
ported to occur in the CSF of patients after a gener-
alized epileptic seizure8, but β-endorphin levels are
normal during seizure-free periods9. Guieu et al.1
found that the nociceptive threshold of patients with
epilepsy did not differ from that of healthy, control
patients. In this study, we measured CPTs prior to
and for 6 months after the administration of valproate
in three patients with traumatic epilepsy. CPTs of
these patients markedly increased. This result supports
the theory that the absence of pain in patients with
epilepsy is mainly caused by valproate. In addition,
their CPT values were higher than the CPTs of patients
with chronic administration of valproate. The decrease
in CPTs of patients with chronic administration of val-
proate is probably caused by tolerance to the pharma-
cological effects after long-term treatment with this
drug.
Neurometer applies a sinusoidal alternation constant
current output to the skin at three frequencies includ-
ing 5 Hz, 250 Hz and 2000 Hz. It is used as a quantita-
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tive test of sensory function for the diagnosis and mon-
itoring of clinical condition. Most neurometric tests
evaluate a single and specific aspect of nerve function.
As the nerve conduction test (NCT) is determined by
the large diameter fibres, this test does not always cor-
relate with clinically painful symptoms17. Vibratory
and thermal tests are also each limited to the excita-
tion of a single specialized type of sensory nerve end-
ing and thus cannot provide a broad-range evaluation
of nerve integrity18. In addition, as CPTs selectively
excite three different subpopulations of axons in a pe-
ripheral nerve with constant current feedback control
circuits, detection of nerve impairment will increase.
The present study showed that an increased sen-
sory threshold was not related to plasma valproate
concentrations. Poor correlation between anticonvul-
sant action and plasma valproate concentrations is sug-
gested19. For pain relief, the best prophylactic effect of
valproate in migraine was at a plasma concentration
of approximately 120 µg ml−1 (700 µmoll−1)20. The
value is approximately three times higher than that of
this study. Plasma concentration of this drug appears
not to correlate with clinical effects.
In conclusion, epileptic patients with valproate had
increased current perception thresholds in all of Aβ,
Aσ and C fibres. The increased sensory threshold
appears to be caused by treatment with valproate
rather than by the epileptic condition, because current
perception threshold in three patients with traumatic
epilepsy markedly increased after the administration
of valproate.
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